These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 30173005)
1. Next generation T-cell therapy for genitourinary malignancies, part A: Introduction and current state of the art. Pantuck M; Palaskas N; Drakaki A Cancer Treat Res Commun; 2018; 17():8-12. PubMed ID: 30173005 [No Abstract] [Full Text] [Related]
2. Next generation T-cell therapy for genitourinary malignancies, part B: Overcoming obstacles and future strategies for success. Pantuck M; Palaskas N; Drakaki A Cancer Treat Res Commun; 2018; 17():1-7. PubMed ID: 30170288 [No Abstract] [Full Text] [Related]
3. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy. Siegler EL; Wang P Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873 [TBL] [Abstract][Full Text] [Related]
4. CAR T cells - what have we learnt? Nat Rev Clin Oncol; 2017 Dec; 15(1):1. PubMed ID: 29242589 [No Abstract] [Full Text] [Related]
5. Beginning the CAR T cell therapy revolution in the US and EU. Grupp S Curr Res Transl Med; 2018 May; 66(2):62-64. PubMed ID: 29656949 [No Abstract] [Full Text] [Related]
6. Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia. Prommersberger S; Jetani H; Danhof S; Monjezi R; Nerreter T; Beckmann J; Einsele H; Hudecek M Curr Res Transl Med; 2018 May; 66(2):37-38. PubMed ID: 29655962 [No Abstract] [Full Text] [Related]
7. Chimeric antigen receptor T cell therapy: 25years in the making. Gill S; Maus MV; Porter DL Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053 [TBL] [Abstract][Full Text] [Related]
8. CAR-T cell therapy in melanoma: A future success story? Simon B; Uslu U Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790 [TBL] [Abstract][Full Text] [Related]
9. Next Steps in the CAR Journey of a Thousand Miles. Brenner MK Mol Ther; 2017 Oct; 25(10):2226-2227. PubMed ID: 28939089 [No Abstract] [Full Text] [Related]
11. Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. Prasad V Nat Rev Clin Oncol; 2018 Jan; 15(1):11-12. PubMed ID: 28975930 [No Abstract] [Full Text] [Related]
12. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy. Liu X; Zhao Y Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200 [TBL] [Abstract][Full Text] [Related]
13. CAR T cells: continuation in a revolution of immunotherapy. Singh AK; McGuirk JP Lancet Oncol; 2020 Mar; 21(3):e168-e178. PubMed ID: 32135120 [TBL] [Abstract][Full Text] [Related]
14. Celyad's novel CAR T-cell therapy for solid malignancies. Lonez C; Hendlisz A; Shaza L; Aftimos P; Vouche M; Donckier V; Machiels JH; Van Den Eynde M; Canon JL; Carrasco J; Odunsi K; Sahebjam S; Rottey S; Braun N; Verma B; Gilham DE; Lehmann FF Curr Res Transl Med; 2018 May; 66(2):53-56. PubMed ID: 29625833 [TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]